TREAT: A Multicentre Cross‐sectional TReatment Evaluation of Apparent Resistant hyperTension in Belgium
The Journal of Clinical Hypertension · 2026-03 · 28 (3)
DOI: 10.1111/jch.70230 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Journal of Clinical Hypertension, online erschienen am 17.03.2026. Verfasst von Brouwers Sofie und 5 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Center Aalst, AZORG Clinic Aalst, Aalst, Belgium. Hauptthemen laut MEDLINE: Hypertension, Antihypertensive Agents. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Servier BeLux.
Abstract (Originalsprache)
The goal of the TREAT study is to estimate the prevalence of true resistant hypertension in a Belgian setting of patients with apparent treatment resistant hypertension (aTRH) and to evaluate which determining factor of pseudo‐resistant hypertension contributes the most to this prevalence. TREAT is a single‐visit, multicentric, non‐interventional, cross‐sectional survey. Inclusion criteria included: patients over 18 years receiving 3 or more antihypertensive molecules and referred to specialized hospital centers for aTRH. A total of 201 eligible patients were included. Only 56.7% of the patients were treated with the guideline recommended triple combination therapy (i.e. renin–angiotensin–aldosterone system inhibitor, calcium channel blocker and thiazide (‐like) diuretic), and only 23.4% were treated with the maximal recommended dose. WCH was present in 8.7% of the 115 patients with available ambulatory blood pressure recordings. Therapeutic adherence was self‐reported as good by 80% of patients, while 20% reported poor or moderate adherence. In this cohort, the prevalence (95% CI) of true resistant hypertension was estimated at 21.9% (14.7%–30.6%). Among patients referred to specialized centers for aTRH, about 3 out of 4 presented with pseudo‐resistant hypertension. The occurrence of WCH and poor adherence appeared rather limited in our study, but half of the participants were polymedicated with non‐recommended combinations of antihypertensive molecules. Inadequate dosing was observed in the majority of patients and a third was not using a single pill combination. Hence, pseudo‐resistant hypertension seems to be mainly associated with the underuse of triple combination therapy and, most likely, with suboptimal dosing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardiovascular Center Aalst, AZORG Clinic Aalst, Aalst, Belgium.
- Department of Experimental Pharmacology, Vrije Universiteit Brussel, Brussels, Belgium.
- Division of Nephrology, University of Liège Hospital (ULiège CHU), Liège, Belgium.
- Groupe Interdisciplinaire de Génoprotéomique Appliquée (GIGA), Cardiovascular Sciences, University of Liège, Liège, Belgium.
- Servier, Brussels, Belgium.
- Department of Public Health and Primary Care, Ghent University, Ghent, Belgium.
Förderung
- Servier BeLux
Zitieren
APA
Sofie, B., Justine, H., Mathilde, C., Bregt, V. N., Dirk, B., & Daniel, M. (2026). TREAT: A Multicentre Cross‐sectional TReatment Evaluation of Apparent Resistant hyperTension in Belgium. The Journal of Clinical Hypertension, 28(3). https://doi.org/10.1111/jch.70230
Vancouver
Sofie B, Justine H, Mathilde C, Bregt VN, Dirk B, Daniel M. TREAT: A Multicentre Cross‐sectional TReatment Evaluation of Apparent Resistant hyperTension in Belgium. The Journal of Clinical Hypertension. 2026;28(3). doi:10.1111/jch.70230
BibTeX
@article{Sofie2026,
author = {Sofie, Brouwers and Justine, Huart and Mathilde, Chabot and Bregt, Van Nieuwenhuyse and Dirk, De Bacquer and Daniel, Munhoz},
title = {TREAT: A Multicentre Cross‐sectional TReatment Evaluation of Apparent Resistant hyperTension in Belgium},
journal = {The Journal of Clinical Hypertension},
year = {2026},
volume = {28},
number = {3},
doi = {10.1111/jch.70230}
}
EUVIMED